On Medicine The impact of treatment access on well-being of patients living with a rare disease: reflections from lived experiences of patients with Familial Chylomicronemia Syndrome

February 26, 2023 18:03 UTC

Trending Today

Canada Post strike impacts upcoming N.B. byelections

Creator of Vancouver's Gastown steam clock dies

Elections N.B. uses radio, social media to spread the word about Dec. 9 vote

The Salvation Army can't fundraise in the Avalon Mall after this year. It all comes down to religion

On Medicine The impact of treatment access on well-being of patients living with a rare disease: reflections from lived experiences of patients with Familial Chylomicronemia Syndrome

Unfortunately, 48% of FCS patients report being misdiagnosed (3). Even with adherence to extremely restricted diet, patients continue to experience pancreatitis and a reduced quality of life (3,5), making patients feel defeated. Glybera, the world’s first approved gene therapy, priced at a million dollars was approved for FCS in Europe. “The FDA seems to have very little understanding of what FCS patients deal with on daily basis. “All they kept looking at were the number of pancreatitis attacks and hospitalizations” several patients shared.

Source: CBC News February 26, 2023 18:03 UTC

Canada should consider excess profit tax to combat grocery prices, researcher says

Kingsbury wins historic fourth world title in dual moguls

More messy weather to hit Toronto this week